Anna Orlova

Kort presentation

Denna text finns inte på svenska, därför visas den engelska versionen.

Publikationer

Senaste publikationer

• Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m (2024)
• Preclinical Evaluation of HER2-Targeting DARPin G3 (2024)
• Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer (2024)
• Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology (2024)
• Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the ^99mTc-Based Imaging of HER2-Expressing Malignant Tumors (2024)

Alla publikationer

Artiklar

• Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m (2024)
• Preclinical Evaluation of HER2-Targeting DARPin G3 (2024)
• Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer (2024)
• Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology (2024)
• Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the ^99mTc-Based Imaging of HER2-Expressing Malignant Tumors (2024)
• Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with ¹⁷⁷Lu (2024)
• GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers (2024)
• Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3 (2024)
• Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [^99mTc]Tc(CO)₃-(HE)₃-Ec1 for Visualization of EpCAM-Expressing Lung Cancer (2024)
• Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation. (2024)
• The GRPR Antagonist [^99mTc]Tc-maSSS-PEG₂-RM26 towards Phase I Clinical Trial (2023)
• Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics (2023)
• ¹⁷⁷Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry (2023)
• Preclinical Evaluation of a Novel High-Affinity Radioligand [^99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA) (2023)
• Phase I clinical evaluation of ^99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer (2023)
• Phase I Trial of [Tc-99m]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors (2023)
• Synthesis, I-123-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures (2023)
• Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity (2023)
• Radionuclide Therapy of HER2-Expressing Xenografts Using [Lu-177]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab (2023)
• Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [Ga-68]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer (2023)
• Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3 (2023)
• Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with Tc-99m and I-125 (2023)
• Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model (2023)
• Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs (2023)
• Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer (2022)
• Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts (2022)
• The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer (2022)
• Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis (2022)
• Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule ¹⁸⁸Re-ZHER2:41071 (2022)
• Preclinical Evaluation of a New Format of Ga-68- and In-111-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT (2022)
• Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands (2022)
• Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3 (2022)
• Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts (2022)
• Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules (2022)
• Direct In Vivo Comparison of ^99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy (2022)
• Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2 (2022)
• Preclinical Evaluation of ^99mTc-Labeled GRPR Antagonists maSSS/SES-PEG₂-RM26 for Imaging of Prostate Cancer (2021)
• Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules (2021)
• Phase I study of ^99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer (2021)
• Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 (2021)
• Affibody-Derived Drug Conjugates Targeting HER2 (2021)
• Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein (2021)
• Radionuclide therapy using ABD-fused ADAPT scaffold protein (2021)
• Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027 (2021)
• Preclinical Evaluation of Tc-99m-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake (2021)
• The Use of a Non-Conventional Long-Lived Gallium Radioisotope ⁶⁶Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR (2021)
• A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers (2021)
• Ga-66-PET-imaging of GRPR-expression in prostate cancer (2021)
• HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers (2021)
• PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology (2021)
• Comparative Evaluation of Novel Lu-177-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting (2021)
• The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer (2021)
• Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model (2021)
• Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model (2021)
• The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy (2021)
• Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer (2020)
• Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer (2020)
• Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1 (2020)
• HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions (2020)
• Imaging using radiolabelled targeted proteins (2020)
• Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches (2020)
• Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. (2020)
• Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model (2020)
• Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer (2020)
• Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting (2020)
• Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules (2020)
• Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules (2020)
• Affibody Molecules as Targeting Vectors for PET Imaging (2020)
• Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1 (2020)
• Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1 (2020)
• Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer (2019)
• Molecular Design of HER3-Targeting Affibody Molecules (2019)
• Comparative Evaluation of Two DARPin Variants (2019)
• Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates (2019)
• Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts (2019)
• Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours (2019)
• Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A (2019)
• Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-Z(EGFR:2377) (2019)
• Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26 (2019)
• Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26 (2019)
• Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer (2019)
• Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart (2019)
• Increase in negative charge of ⁶⁸Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules (2019)
• Optimization of HER3 expression imaging using affibody molecules (2019)
• Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake (2019)
• Selection of the optimal macrocyclic chelators for labeling with ¹¹¹In and ⁶⁸Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 (2019)
• Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3 (2019)
• Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 (2019)
• Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging (2019)
• Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting (2019)
• Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs (2018)
• Affibody-derived drug conjugates (2018)
• Selection of the most optimal ADAPT6-based probe for imaging of HER2 using PET and SPECT (2018)
• Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe (2018)
• Same-day imaging using small proteins (2018)
• Radionuclide tumor targeting using ADAPT scaffold proteins (2018)
• Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with ¹¹¹In and ⁶⁸Ga (2018)
• Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate (2018)
• GRPR-targeted radiotherapy using the Lu-177-labeled GRPR-antagonist DOTAGA-PEG(2)-RM26 (2018)
• Selection of optimal macrocyclic chelator for high contrast PET imaging of gastrin releasing peptide receptor using cobalt-labeled bombesin antagonist RM26 (2018)
• Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab (2018)
• Imaging contrast of HER3 expression using monomeric affibody-based imaging probe can be improved by co-injection of affibody trimer (2018)
• Influence of composition of cysteine-containing peptide-based chelators on biodistribution of ^99mTc-labeled anti-EGFR affibody molecules (2018)
• Comparative evaluation of anti-EFGR affibody molecules labelled with gallium-68 and zirconium-89 using desferrioxamine B as a chelator (2018)
• Preclinical Evaluation of [Ga-68]Ga-DFO-ZEGFR:2377 (2018)
• Optimization of molecular design of Ga-68-labeled affibody molecule for PET imaging of HER3 expression (2018)
• PP15 89Zr-Siderophore-Affibody conjugates for imaging EGFR expression (2018)
• Cyclic versus Noncyclic Chelating Scaffold for Zr-89-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression (2018)
• Molecular design of radiocopper-labelled Affibody molecules (2018)
• Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Molecular Imaging of HER2 Expression in Cancer Using SPECT (2018)
• Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors (2018)
• Development of a PET Imaging Approach for Selection of Patients for Affibody-Based PNA-Mediated Pretargeted Radionuclide Therapy (2018)
• Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy (2018)
• Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting (2018)
• In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin- binding therapeutic affibody construct (2017)
• The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule (2017)
• Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m (2017)
• Radiocobalt-labeled anti-HER1 affibody molecule DOTA-Z(EGFR:2377) for imaging of low HER1 expression in prostate cancer pre-clinical model (2017)
• Novel high affinity affibody for radionuclide imaging of VEGFR2 in glioma vasculature (2017)
• High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26 (2017)
• GRPR-Targeted Radiotherapy (2017)
• Influence of composition of cysteine-containing peptide based chelators on biodistribution of Tc-99m-labelled anti-EGFR affibody molecules (2017)
• Optimization of affibody molecule for imaging of HER3 expression (2017)
• Evaluation of radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression (2017)
• Optimal molecular design of radiocopper-labelled affibody molecules (2017)
• Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with Cu-64 Using NOTA and NODAGA (2017)
• Improving of molecular design of a novel Affibody-fused HER2-recognising anticancer toxin using radionuclide-based techniques (2016)
• Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin (2016)
• Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting (2016)
• Comparative evaluation of Lu-177-HP2 and In-111-HP2, secondary agents for affibody-based PNA-mediated radionuclide pretargeting (2016)
• Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR (2016)
• PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR (2016)
• Evaluation of Affibody Molecules for Radionuclide Imaging of Carbonic Abhydrase IX Expression In Vivo (2016)
• Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX (2016)
• Influence of the N-terminal amino acid sequence on imaging properties of In-111-labeled anti-HER2 scaffold protein ADAPT6 (2016)
• Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6 (2016)
• Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors (2016)
• Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. (2016)
• Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct Z(VEGFR2)-Bp(2) (2016)
• Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. (2016)
• In vivo evaluation of pharmacokinetics, tumors targeting and therapeutic efficacy of a novel format of HER3-targeting affibody molecule with prolonged blood circulation (2016)
• Imaging of EGFR Expression Using 99mTC-Labelled ZEGFR:2377 Affibody Molecule (2016)
• Development and Evaluation of Radiocobalt-labelled Affibody Molecule for Next Day PET Imaging of HER3 Expression (2016)
• Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients (2016)
• Synthesis of ¹¹C-labelled Sulfonyl Carbamates via a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols and [¹¹C]CO (2016)
• Synthesis of C-11-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [C-11]CO (2016)
• Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT (2016)
• Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules (2016)
• Affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting (2015)
• Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients (2015)
• Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors (2015)
• The use of radiocobalt as a label improves PET imaging of EGFR using DOTA-conjugated affibody molecules (2015)
• ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers (2015)
• Feasibility of Affibody molecule-based PNA-mediated pretargeting (2015)
• Influence of Histidine-Containing Tags on Biodistribution of Radiolabelled ADAPT-Based Imaging Probes (2015)
• Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression (2015)
• Development of radiocobalt-labeled GRPR antagonist NOTA-PEG2-RM26. (2015)
• Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or x-ray radiation with three different LigandTracer® devices (2015)
• Influence of chelators on targeting properties of In-111 and Ga-68 labeled GRPR antagonist (2015)
• Affibody-mediated PET imaging of HER3 expression in malignant tumours (2015)
• Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity (2015)
• The effect of macrocyclic chelators on the targeting properties of the ⁶⁸Ga-labeled gastrin releasing peptide receptor antagonist PEG₂-RM26 (2015)
• Comparing the measured affinity of (111) In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracer (R) devices (2015)
• Good manufacturing practice compliant production of a Ga-68-labelled Affibody agent for breast cancer imaging (2015)
• Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸Re (2014)
• Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine (2014)
• ¹⁸⁸Re-Z_HER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors (2014)
• In Vitro Therapy Modeling of HER2 Targeting Therapy in Disseminated Prostate Cancer (2014)
• 111In-labeled NOTA-conjugated Affibody molecules for visualization of HER3 expression in malignant tumors (2014)
• Development of ADAPT6 as a new scaffold protein for radionuclide molecular imaging (2014)
• Position for Site-Specific Attachment of a DOTA Chelator to Synthetic Affibody Molecules Has a Different Influence on the Targeting Properties of 68Ga- Compared to 111In-Labeled Conjugates. (2014)
• Evaluation of 99mTc-ZIGF1R:4551-GGGC Affibody Molecule, a New Construct for Imaging the Insulin-like Growth Factor Type 1 Receptor Expression (2014)
• Influence of chelators on biodistribution and targeting properties of GRPR antagonist (2014)
• Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3 08699 affibody molecule (2014)
• PET Imaging of HER3-Expression in Tumours Using a 68Ga-Labeled Affibody Molecule (2014)
• Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with (18)F-4-Fluorobenzaldehyde (2014)
• Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer (2014)
• Gallium-68-labeled affibody molecule for PET imaging of PDGFR beta expression in vivo (2014)
• Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRβ Expression in Vivo (2014)
• Development of a I-124-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer (2014)
• Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591 (2014)
• Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes. (2014)
• The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a Ga-68-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin (2014)
• GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination (2014)
• Selection of an optimal cysteine-containing peptide-based chelator for labeling of Affibody molecules with 188-Re (2013)
• Influence of Nuclides and Chelators on Imaging Using Affibody Molecules (2013)
• In Vivo and In Vitro Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors (2013)
• HAHAHA, HEHEHE, HIHIHI, or HKHKHK (2013)
• Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging (2013)
• Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification (2013)
• Increase of HER2 expression in prostate cancer cell lines as reaction on external irradiation (2013)
• [^99mTc(CO)₃]⁺-(HE)₃-Z_IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours (2013)
• Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein (2013)
• Feasibility of radionuclide imaging of HER3-expressing tumours using technetium-99m labeled affibody molecules (2013)
• Feasibility of radionuclide imaging of HER3-expressing tumors using affibody molecules (2013)
• Influence of macrocyclic chelators on biodistribution and targeting properties of 68Ga-labeled synthetic Affibody molecules. Comparison with 111In-labeled counterparts (2013)
• Influence of Macrocyclic Chelators on the Targeting Properties of ⁶⁸Ga-Labeled Synthetic Affibody Molecules (2013)
• HAHAHA-, HIHIHI-. HKHKHK. HHHHHH- and HEHEHE- tags (2013)
• In vivo imaging of PDGFR beta expression using In-111-DOTA-Z09591 Affibody molecule (2013)
• Imaging of PDGFRbeta expression in vivo using Affibody molecule In-111-DOTA-Z09591 (2013)
• Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging (2013)
• GRPR antagonist NOTA-P2-RM26 labeled with fluorine-18 (2013)
• In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging (2013)
• Detecting ligand interactions with G protein-coupled receptors in real-time on living cells (2013)
• (AlF)-F-18-labelling of NOTA-P2-RM26 and its evaluation as a PET ligand for GRPR/BB2 (2013)
• Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with ¹¹¹In using a maleimido derivative of NODAGA (2012)
• Comparative evaluation of anti-HER2 affibody molecules labeled with 68Ga and 111In using maleimido derivatives of DOTA and NODAGA (2012)
• Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of (99m)Tc-labeled recombinant Affibody molecules (2012)
• Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line (2012)
• Influence of DOTA chelator position on biodistribution and targeting properties of 111 In-labelled anti-HER2 affibody molecules (2012)
• Liver uptake of radiolabeled targeting proteins and peptides (2012)
• Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for ^99mTc-labelling at the C terminus (2012)
• Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. (2012)
• Development of 124I-labelled anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer (2012)
• Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of In-111-Labeled Synthetic Anti-HER2 Affibody Molecules (2012)
• Direct comparison of In-111-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging (2012)
• Site-specific radioiodination of HER2-targeting affibody molecules using iodophenetylmaleimide decreases renal uptake of radioactivity (2012)
• 99mTc(CO)3-HEHEHE-ZIGF1R:4551 affibody molecule, a poteintial imaging agent for visualization of insulin-like growth factor-1 receptor in malignant tumors (2012)
• Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹In-DOTA-Z_IGF1R:4551 (2012)
• Tumor Targeting Using Affibody Molecules (2012)
• Synthesis and characterization of a high affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging (2012)
• Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with Tc-99m, In-111 and I-125 (2011)
• Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts (2011)
• Imaging agents for in vivo molecular profiling of disseminated prostate cancer - targeting EGFR receptors in prostate cancer (2011)
• Imaging agents for in vivo molecular profiling of disseminated prostate cancer (2011)
• Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules (2011)
• Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate (2011)
• Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels (2011)
• Engineering of C-terminal cysteine-containing peptide-based chelators improves biodistribution of HER2-targeting ^99mTc-labeled Affibody molecules (2011)
• Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties (2011)
• Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold (2010)
• Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules (2010)
• Quantification of internalization of EGFR-binding Affibody molecules (2010)
• Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. (2010)
• Influence of an aliphatic linker between DOTA and synthetic Affibody molecule on targeting properties (2010)
• Re-186-maSGS-Z(HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours (2010)
• HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [Tc-99m(CO)(3)](+), and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation (2010)
• HEHEHE (2010)
• Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets (2010)
• Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR In-111-DOTA-Z(EGFR:2377) Affibody molecule (2010)
• Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response (2010)
• A HER2-binding Affibody molecule labelled with ⁶⁸Ga for PET imaging (2010)
• HER2 targeting with Tc-99m-labeled second generation synthetic Affibody molecule (2010)
• Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys⁶¹]-Z_HER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors (2010)
• Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine (2009)
• Positioning of Tc-99m-chelators influences radiolabeling, stability and biodistribution of Affibody molecules (2009)
• Synthesis and chemoselective intramolecular cross-linking of a HER2-binding Affibody (2009)
• On the selection of a tracer for PET imaging of HER2-expressing tumors (2009)
• Update on Affibody molecules for in vivo imaging of targets for cancer therapy (2009)
• Affibody molecules for epidermal growth factor receptor targeting in vivo (2009)
• Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding (2009)
• The influence of Bz-DOTA and CHX-AaEuro(3)-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules (2009)
• Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging (2009)
• Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules (2008)
• Targeting EGFR and HER2 with 211At-labeled molecules (2008)
• Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake (2008)
• Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule (2008)
• In vivo and in vitro uptake of In-111, delivered with the affibody molecule(Z(EGFR:955))(2), in EGFR expressing tumour cells (2008)
• Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules (2008)
• Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of ^99mTc-labeled anti-HER2 Affibody molecules (2008)
• Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2 (2008)
• Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence (2007)
• ^99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule (2007)
• Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma (2007)
• Update (2007)
• Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors (2007)
• Synthetic affibody molecules (2007)
• Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors (2007)
• In Vivo Evaluation of Cysteine-Based Chelators for Attachment of 99mTc  to Tumor-Targeting Affibody Molecules (2007)
• Affibody molecules (2007)
• Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule (2007)
• (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors (2007)
• Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand (2007)
• Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated (2006)
• Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI) (2006)
• Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI) (2006)
• Tumor imaging using a picomolar affinity HER2 binding affibody molecule (2006)
• Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors (2006)
• Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice (2006)
• 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors (2006)
• In vitro characterization of 211 At-labeled antibody A33 (2005)
• [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo (2005)
• An Aminoacridine Derivative for Radionuclide Therapy: Dna-Binding Properties Studied in a Novel Cell-Free in vitro Assay (2005)
• An aminoacridine derivative for radionuclide therapy (2005)
• Evaluation of ((4-Hydroxyphenyl)ethyl)maleimide for Site-Specific Radiobromination of Anti-HER2 Affibody (2005)
• Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET (2005)
• Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker (2004)
• Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives (2004)
• Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB1 H11 (2004)
• Targeting against epidermal growth factor receptors (2004)
• Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media (2004)
• [177Lu]Bz-DTPA-EGF (2004)
• Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice (2004)
• Feasibility of isotopic exchange in system [125I] iodide – undecahydro-iodo-closo-dodecaborate (2-) anion (2003)
• Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF (2003)
• [111In]Bz-DTPA-hEGF (2003)
• Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides (2003)
• [111In]-DTPA-hEGF and [111In]-Bz-DTPA-hEGF (2002)
• Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33 (2002)
• [111In] benzyl-DTPA-EGF, a new potential radiopeptide for targeting of glioma (2002)
• Cellular processing of iodinated and astatinated trastuzumab in cultured SK-BR-3 breast cancer cells (2002)
• The use of benzyl isothiocyanate derivative of closo-dodecaborate dianion for indirect radioiodination and radiobromination of monoclonal antibodies (2002)
• Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma loclizing agent (2002)
• Cellular processing of indirectly astatinated and iodinated mAb A33 in SW1222 cultured cells (2001)
• Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET (2000)
• Effect of ionizing radiation on the labeling of closo-dodecaborate(2-) anion with 125I (2000)
• Synthesis of [211At] N-[8-(acridin-9-ylamino)-octyl]-3- astatobenzamide, an astatinated DNA intercalator (2000)
• Cellular processing of (125)I- and (111)in-labeled epidermal growth factor(EGF) bound to cultured A431 tumor cells (2000)
• Cellular processing of ¹²⁵I- and ¹¹¹in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells (2000)
• Closo-dodecaborate(2-)anion as a potential prosthetic group for attachment of astatine to proteins (2000)
• Optimization of iodination of [125I]-N-succinimidyl-para-iodobenzoate using Chloromine-T for labeling of proteins (2000)
• Intercalators labelled with Auger emitting nuclides (1999)
• Closo-dodecaborate(2-) as a linker for iodination of macromolecules (1999)
• Labelling and in vivo evaluation of closo-dodecaborate as a linker for attachment of iodine to radiopharma-ceuticals (1997)
• Labelling of boron containing compounds with halogen isotopes (1997)
• Pharmacokinetics in tumour-bearing rats of directly and indirectly ⁷⁶Br-brominated MAb A33
• Synthesis and Preclinical Evaluation of GRPR Antagonist [¹⁸F]-MeTz-PEG₂-RM26 for Position Emission Tomography
• Polyhedral boron clasters as linkers for attachment of radiohalogens to tumor targeting proteins. II. Radioiodination of monoclonal antibody using potassium [125I]-4-(isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (Iodo-DABI)

Kapitel

• Methods for radiolabelling of monoclonal antibodies (2014)
• Radiohalogenated Polyhedral Borate Anaions for use in Targeted Oncological Radionuclide Therapy, Some Recent Developments (2003)
• Effect of ionising radiation on the labelling of closo-dodecaborate (2-) anion (2000)
• Closo-dodecaborate (2-) anion as a prosthetic group for labelling proteins with a astatine (2000)

Övrigt

• Pharmacokinetics in tumour-bearing rats of directly and indirectly 76Br-brominated MAb A33 (2002)